Development of a therapeutic monoclonal antibody that targets secreted fatty acid–binding protein aP2 to treat type 2 diabetes.

The article focuses findings of a study on development of a therapeutic monoclonal antibody at targets secreted fatty acid–binding protein aP2 to treat type 2 diabetes. It states that Serum aP2 levels are markedly elevated in mouse and human obesity and strongly correlate with metabolic complications, and mentions that the structure of the aP2-CA33 complex and resolved the target epitope. It infers that antibody had no effect in aP2-deficient mice, demonstrating its target specificity.